Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD and MAD Study of PPI-1011
NCT05969977Phase 1Completed
- Sponsor
- Med-Life Discoveries
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rhizomelic chondrodysplasia punctata (RCDP) comparing PPI-1011 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jun 2023; status: completed.
02
Drugs
PPI-1011
03
Conditions
rhizomelic chondrodysplasia punctata (RCDP)
Beyond the preview
Go deeper on NCT05969977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969977.